Filing Flows › Celldex Therapeutics (CLDX) › Q4 2025
Celldex Therapeutics (CLDX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 25, 2026
Celldex Therapeutics (CLDX) reported revenue of $121K for the fourth quarter 2025 (Q4 2025), -90% from a year earlier.
Celldex Therapeutics, Q4 2025: revenue $121K (-90% year over year), net loss $81.3M, operating cash flow −$63.9M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121K | — | -90% |
| Operating profit | −$87.2M | — | — |
| Net earnings | −$81.3M | — | — |
| Operating cash flow | −$63.9M | — | — |
What changed
Revenue was $121K in Q4 2025, down 90% year over year. Contracts and grants was the largest line at 67% of revenue.
Operating costs exceeded revenue by $87.2M, an operating margin of -72027.3%. Total costs grew 53% against a revenue fall of 90%. The fastest-growing cost line was Research & development (+60%). The quarter ended with a net loss of $81.3M.
Operating cash flow was −$63.9M. Non-cash charges added back $816K of depreciation and amortization and $8.9M of share-based compensation. Working capital and other items added $7.7M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$65.2M.
Questions
What was Celldex Therapeutics' revenue in the fourth quarter 2025?
Celldex Therapeutics (CLDX) reported revenue of $121K for the fourth quarter 2025 (Q4 2025), -90% from a year earlier.